



COMMUNICABLE DISEASES INTELLIGENCE

ISSN 0725 - 3141 VOLUME 20 NUMBER 25 9 December 1996

CONTENTS

ARTICLES

Page

High level aminoglycoside resistance in Enterococcal blood culture isolates David Paterson, Janet Bodman, Mee Len Thong	532
Update on bat lyssavirus	535
CDI subject index, 1996	535
CDI author index, 1996	541
CDI reviewers, 1996	543

NOTICE TO READERS

A note from the editor	544
------------------------	-----

OVERSEAS BRIEFS

544

COMMUNICABLE DISEASES SURVEILLANCE

544

Acting Editor : Ana Herceg
Deputy Editor : Graham
Andrews
Assistant Editor : Margaret Curran

Editorial Advisory Board: Charles Watson (Chair), Margaret Burgess, Scott Cameron, Cathy Mead, Jeffrey Hanna, John Kaldor, Margery Kennet, Christine Roberts

Editorial and Production Staff: Ross Andrews, Htoo Myint, Michelle Charlton, John Irvine, , Barbara Jenkins, Corina Young

Contributions covering any aspect of communicable diseases are invited. Instructions to authors can be found in CDI 1995; 20: 13.

CDI is produced fortnightly by the AIDS/Communicable Diseases Branch, Department of Health and Family Services, GPO Box 9848 Canberra ACT 2601, Fax: (06) 289 7791 Telephone : (06) 289 1555

Opinions expressed in CDI are those of the authors and not necessarily those of the Department of Human Services and Health or other Communicable Diseases Network - Australia affiliates. Figures given may be subject to revision.

CDI is available on the CDI Bulletin Board System on (06) 281 6695, and via Internet on 'ftp://ftp.health.gov.au' in directory /pub/CDI and on 'http://www.health.gov.au' in '/hfs/pubs/cdi/cdihtml.htm.'

Consent for copying in all or part can be obtained from Manager, Commonwealth Information Service Australian Government Publishing Service, PO Box 84 Canberra ACT 2601



COMMONWEALTH
DEPARTMENT OF
HEALTH AND FAMILY SERVICES

HIGH LEVEL AMINOGLYCOSIDE RESISTANCE IN ENTEROCOCCAL BLOOD CULTURE ISOLATES

David Paterson¹, Janet Bodman and Mee Len Thong, Royal Brisbane Hospital, Herston Road, Herston, Queensland 4006

Abstract

Enterococci may display high level resistance to aminoglycosides, in which case synergy with cell-wall active antibiotics will be lost. All enterococcal blood culture isolates at Royal Brisbane Hospital have been screened by agar dilution for high level resistance to gentamicin and streptomycin since 1989. Of 110 isolates of *Enterococcus faecalis*, 16% displayed high level resistance to gentamicin and 10% showed high level resistance to streptomycin. Four isolates had high level resistance to both antibiotics. None of 23 *Enterococcus faecium* isolates displayed high level resistance to gentamicin and only one to streptomycin. Two *Enterococcus faecium* isolates were resistant to amoxycillin but none to vancomycin. There has been no apparent increase in high level aminoglycoside resistance from 1989 to 1996. High level gentamicin resistant isolates were relatively more common in liver transplant patients. Like vancomycin-resistant enterococci, isolates that are high level resistant to aminoglycosides can be spread by the hands of staff members. Preventing the nosocomial transmission of high level aminoglycoside-resistant enterococci follows the same general principles of preventing transmission of other resistant enterococci.

Comm Dis Intell 1996;20:532-535.

Introduction

Enterococci intrinsically display resistance to low levels of aminoglycosides. However when an aminoglycoside is combined with a cell-wall active antibiotic (for example, amoxycillin or vancomycin), synergistic killing of the enterococcus results. In the last decade, high level resistance of enterococci to aminoglycosides has become an important clinical problem. If the organism exhibits high level resistance to an aminoglycoside, no synergy will be achieved when that aminoglycoside is combined with a cell-wall active antibiotic. This has most relevance in the treatment of serious infections such as endocarditis. Failure of cell-wall active agents used alone has been well described in this context.

Like vancomycin-resistant enterococci, high level aminoglycoside-resistant enterococci have been well recognised to be transmitted within hospitals¹. Like many other antibiotic-resistant organisms, transmission is often via the hands of health care workers.

We reviewed the laboratory and clinical records of more than 100 patients with enterococcal bacteraemia from 1989 to 1996 to determine whether there was any rise in high level aminoglycoside resistance over that time and whether it has had any impact on the clinical outcome.

Methods

From January 1989 to July 1996, enterococcal blood culture isolates from the Royal Brisbane Hospital complex (Royal Brisbane Hospital, Royal Childrens Hospital and Royal Womens Hospital) were recorded on a database. A commercial system was used to detect growth (BACTEC NR 660 up to mid-1992, and then BacT / Alert). The organisms

were identified to the genus level as *Enterococcus* using standard laboratory tests based on Gram stain, catalase reaction, bile tolerance, ability to hydrolyse aesculin, tolerance to 6.5% sodium chloride and pyruvate utilisation. If the organism did not utilise pyruvate, it was speciated using the API 20 STREP, yellow pigment production and motility test.

All enterococcal isolates were tested routinely by the agar dilution method using Steer's replicator. Enterococcal isolates were screened for high level resistance to aminoglycosides using agar plates containing gentamicin at 500 mg/L or streptomycin at 2000 mg/L.

A retrospective review of patients' charts was performed to collect data on underlying conditions, source of infection (nosocomial or community acquired), antibiotic usage and clinical outcome. Nosocomial acquisition of bacteraemia was defined as present if positive blood cultures were drawn more than 48 hours after hospital admission. Relapse was defined as blood culture positivity greater than 72 hours after the most recent positive blood culture was taken. Differences in outcome and other variables were assessed using the software package STATA.

Results

There were 136 episodes of enterococcal bacteraemia of which 110 were with *Enterococcus faecalis* (*E. faecalis*), 23 with *Enterococcus faecium*, two with *E. durans* and one with *E. casseliflavus*. The resistance of these isolates to gentamicin and streptomycin is shown in detail in Table 1. Figures 1 and 2 illustrate the resistance patterns of the enterococcal blood culture isolates from 1989 to 1996. Over this period, 16% of *E. faecalis* isolates displayed high level resistance to

1. Current affiliation: JJ Sullivan, NJ Nicolaides and Partners, 134 Whitmore Street, Taringa, Queensland 4068.

Table 1. Blood culture isolates of enterococci at the Royal Brisbane Hospital, 1989 to 1996

Species of enterococcus	Number of blood culture isolates								
	1989	1990	1991	1992	1993	1994	1995	1996	Total
<i>Enterococcus faecalis</i>	13	17	10	13	13	19	15	10	110
High level resistance to gentamicin	1	2	3	1	1	4		1	13
High level resistance to streptomycin	1	2	1			2	1		7
High level resistance to both agents	1		1			1		1	4
<i>Enterococcus faecium</i> ¹	6	1	2	3	4	3	3	1	23
High level resistance to streptomycin	1								1
Amoxycillin resistant						2			2
<i>Enterococcus durans</i>					1			1	2
<i>Enterococcus casseliflavus</i>						1			1
TOTAL	19	18	12	16	18	23	18	12	136

1. No *E. faecium* isolates displayed high level resistance to gentamicin or vancomycin resistance.

gentamicin and 10% to streptomycin. Four isolates were resistant to both antibiotics. Proportions of resistant isolates have fluctuated widely from year to year, but showed a slight decline since peaking in 1991. No *E. faecium* isolates displayed high level resistance to gentamicin and only one to streptomycin. Two isolates of *E. faecium* were amoxycillin resistant. Neither isolate was a beta-lactamase producer. No blood culture isolate was vancomycin resistant.

The medical records pertaining to 100 cases were available for review. Sixty-seven episodes occurred in 62 adult patients (three of whom were in the Royal Womens Hospital) and 33 episodes occurred in 30 paediatric patients (six of whom were in the Neonatal Intensive Care Unit). The ages of patients ranged from one day old to 93 years old. Four of the patients were Japanese children who came to Aus-

tralia for liver transplantation. There have been no molecular epidemiologic studies performed to determine whether there was a common clone of resistant enterococci in patients from the liver transplant ward. Two adults (one American and one Indonesian) also came to the hospital for specialised medical care. The remaining patients were Australian residents who presumably had acquired their enterococcal species in Australia.

Twelve of the 100 patients whose charts could be reviewed had enterococcal isolates with high level resistance to gentamicin. Risk factors and outcomes associated with infection in patients with enterococcal bacteraemia with and without high level resistance to gentamicin is presented in Table 2. Patients with high level resistance to gentamicin were significantly more likely to be liver transplant recipients ($p=0.04$). Two patients with high level



Figure 1. Enterococcal bloodstream isolates with high level resistance to gentamicin, 1989 to 1996**Figure 2. Enterococcal bloodstream isolates with high level resistance to streptomycin, 1989 to 1996**

Table 2. Risk factors and outcomes associated with enterococcal bacteraemia with and without high level resistance to gentamicin

	Number with high level resistance to gentamicin (%) (n=12)	Number without high level resistance to gentamicin (%) (n=88)	Level of statistical significance
Risk factors			
Female	6 (50)	41 (47)	NS
Polymicrobial bacteraemia	5 (42)	30 (34)	NS
Nosocomial acquisition	11 (92)	63 (72)	NS
Organ transplant	3 (25)	4 (5)	p = 0.04
Primary bacteraemia	5 (42)	48 (55)	NS
Line-related sepsis	0 (0)	19 (22)	NS
Urosepsis	3 (25)	8 (9)	NS
Endocarditis	2 (17)	1 (1)	p = 0.04
Other site	2 (17)	12 (14)	NS
Outcome			
Relapse	1 (8)	8 (9)	NS
Death within one month	3 (25)	19 (22)	NS

NS: Not significant.

resistance to gentamicin had clinical diagnoses of endocarditis. One patient was treated with vancomycin alone and died of unrelated causes three weeks later. One patient was treated with penicillin and gentamicin, despite the in vitro susceptibility report, and survived.

Paradoxically, patients with high level resistance to gentamicin were more likely to receive an aminoglycoside than patients without high level resistance ($p=0.03$). Eighty-three per cent of patients with high level resistance to gentamicin were treated with a cell-wall active antibiotic and an aminoglycoside. More than 50% of these patients received the combination therapy for more than one week. An adverse clinical outcome (death within one month or relapse of enterococcal bacteraemia) was not more common in patients with high level resistance to gentamicin, although the numbers of patients studied was small.

Discussion

High level aminoglycoside resistance in enterococci has been well established at Royal Brisbane Hospital since testing began in 1989. Since then, about 16% of *E. faecalis* isolates have displayed high level resistance to gentamicin and 10% have shown high level resistance to streptomycin.

The rates of high level resistance to gentamicin appear somewhat higher than the percentage of 7.3% (of 70 bacteraemic isolates) found in a recent multicentre Australia-wide survey². However, the rates of high level resistance to streptomycin are lower than those found in other parts of Australia (17.7% for *E. faecalis* and 38.9% for *E. faecium* blood culture isolates). The percentage of *E. faecalis* isolates exhibiting high level resistance to gentamicin is certainly less than the 70% recently described in a study on entero-

coccal isolates in liver transplant recipients at the Mayo Clinic³.

The opening of a new transplantation ward may have decreased crowding of patients and reduced environmental contamination with resistant enterococci, thereby in part explaining the decrease in high level gentamicin-resistant isolates in 1995 and 1996.

It is well known that inter-hospital and even inter-country transfer of resistant organisms can occur. Screening for rectal carriage of resistant enterococci and cephalosporin-resistant Enterobacteriaceae may be prudent in patients referred for transplantation or other specialised attention such as intensive care. Preventing the transmission of high level aminoglycoside-resistant enterococci follows the same general principles as preventing transmission of other resistant enterococci. Attention to hand washing by staff members is a key intervention. Single room isolation of patients with aminoglycoside-resistant enterococci has not been practised at our hospital.

It is surprising that more than 50% of patients with high level resistance to gentamicin were treated with this drug in combination with a cell-wall active agent despite knowledge of the in vitro susceptibility result. Theoretically the use of an aminoglycoside in this situation is more likely to result in adverse effects such as nephrotoxicity and ototoxicity, without any benefit being achieved for the patient. Drug toxicity was not determined in this study.

Uptake of aminoglycosides into enterococci depends on aerobic oxidative metabolism. The anaerobic metabolism of enterococci leads to their intrinsic resistance to low concentrations of these antibiotics. There are a number of mechanisms for acquiring high level resistance to the aminoglycosides⁴. High level resistance to gentamicin is mediated by aminoglycoside modifying enzymes (a fused 6'-acetyltransferase / 2''-phosphotransferase). These en-

zymes alter the aminoglycoside molecule so that it binds poorly to the ribosome (the site of action of aminoglycosides). The fused enzyme that produces high level gentamicin resistance produces resistance to synergy with all other clinically used aminoglycosides except streptomycin. Thus if a patient has high level resistance to gentamicin, streptomycin is the only option for synergy. Unfortunately enterococci with high level resistance to both gentamicin and streptomycin, and therefore all aminoglycosides, occur. Four such isolates were found in our series. Such a finding has dire consequences for a patient with enterococcal endocarditis. The genes coding for these aminoglycoside-modifying enzymes are found on plasmids, with the exception of a 6'-acetyltransferase of *E. faecium* which is chromosomally encoded. This enzyme is produced by all strains of *E. faecium*, and inactivates tobramycin, netilmicin and kanamycin⁵. These drugs should never be used for synergistic action against *E. faecium*.

References

1. Zervos MJ, Kauffman CA, Therasse PM *et al*. Nosocomial infection by gentamicin-resistant *Streptococcus faecalis*: An epidemiologic study. *Ann Intern Med* 1987;106:687-691.
2. Bell JM, Fernandes CJ, Coombs GW. Antimicrobial resistance in *Enterococcus* in Australia. Abstract P21.2, *Microbiol Aust* 1996;17:A68.
3. Patel R, Badley AD, Larson-Keller J *et al*. Relevance and risk factors of enterococcal bacteremia following liver transplantation. *Transplant* 1996;61:1192-1197.
4. Leclercq R, Dutka-Malen S, Brisson-Noel A *et al*. Resistance of enterococci to aminoglycosides and glycopeptides. *Clin Infect Dis* 1992;15:495-501.
5. Moellering RC. *Enterococcus* species, *Streptococcus bovis* and *Leuconostoc* species. In, GL Mandell, JE Bennett, R Dolin, editors. *Principles and practice of infectious diseases* (4th edition) New York: Churchill Livingstone, 1995:1826-1835.

Update on bat lyssavirus

The second meeting of the Lyssavirus Expert Group was held on 3 December 1996. The group reviewed new information on the virus. This included the first identification of lyssavirus in an insectivorous bat. A yellow-bellied sheath-tail bat, *Saccolaimus flaviventris*, was found on the ground and unable to fly, near Toowoomba, Queensland. Following euthanasia, the animal was found to have a non-suppurative encephalitis on histopathology and was lyssavirus positive by immunofluorescence.

Research priorities for the bat lyssavirus were discussed by the group. These included both wildlife and human aspects. This research will further inform public health action required for the control of the virus.

The group noted that while current advice to medical practitioners and public health authorities stands¹, there is the possibility of inapparent exposure to lyssavirus. This has been the experience with rabies in the United States of America^{2,3}. The group recommended that neurologists and intensive care physicians be alerted to look for lyssavirus infection in cases of unexplained encephalopathy. The recommendations of the National Health and Medical Research Council for post-exposure vaccination of previously vaccinated persons for rabies should be applied to lyssavirus⁴.

The group recommended that the National Health and Medical Research Council *Australian Immunisation Procedures Handbook* be updated to include advice on pre- and post-exposure prophylaxis for lyssavirus.

References

1. Lyssavirus Expert Group. Prevention of human lyssavirus infection. *Comm Dis Intell* 1996;20:505-507.
2. Human rabies - Texas, Arkansas and Georgia, 1991. *MMWR Morb Mort Wkly Rep* 1991;40:765-769.
3. Human rabies - New York, 1993. *MMWR Morb Mort Wkly Report* 1993;42:799-806.
4. National Health and Medical Research Council. *The Australian immunisation procedures handbook* 5th edition. Canberra: Australian Government Publishing Service, 1995.

CDI SUBJECT INDEX, 1996

A

Acellular vaccines for pertussis; 192

Acquired immune deficiency syndrome

See HIV and AIDS

Acute flaccid paralysis

Reporting cases; 120, 405

Surveillance in Australia; 403

See also Poliomyelitis

Adverse Events Following Vaccination Surveillance Scheme

Surveillance data in *CDI*; 11

Surveillance reports; 17, 72, 126, 177, 226, 268, 311, 346, 434, 550

AGSP

See Gonococcal surveillance reports

AIDS

See HIV and AIDS

Antibiotics

Are we running out? 166

Antibiotic resistance

Aminoglycoside resistant enterococci; 532

Gonococci, Western Pacific Region, 1995; 425

MRSA, sodium fusidate resistance in Western Australia; 492

Network on Antimicrobial Resistance Monitoring; 259

Vancomycin-resistant enterococci; 400, 402

Arcanobacterium haemolyticum causing diphtheria-like illness; 64

ASPREN

See Australian Sentinel Practice Research Network

Australian Capital Territory

Haemophilus influenzae type b vaccination coverage; 256

Australian Childhood Immunisation Register; 14

Australian Encephalitis, Sentinel Chickens

See Sentinel Chicken Surveillance Programme

Australian Gonococcal Surveillance Program

See Gonococcal surveillance reports

Australian Sentinel Practice Research Network

Recruitment of general practitioners; 495

Surveillance data in *CDI*; 11

Surveillance reports; 17, 46, 98, 125, 153, 176, 204, 225, 248, 268, 290, 310, 331, 346, 360, 378, 411, 433, 471, 487, 499, 528, 548

B

Bat

Equine morbillivirus

Possible host; 262, 476

Screening of carers for; 477

Lyssavirus

Human case of encephalitis; 504

Human health aspects; 325, 535

Prevention of human infection; 505, 535

Bordetella pertussis

See Pertussis

Bovine spongiform encephalopathy

Australian response; 170

Australian task force; 198

Enquiries; 216

Possible human risks; 197

United Kingdom; 169

Buffalopox

Overseas updates; 198

C

Campylobacteriosis

Queensland, five year review; 478

CDI

Editorial Advisory Board; 13

Editorial changes; 41, 372

Electronic distribution; 42, 341

Instructions to authors; 13

Readership survey; 39

Reviewers, 1996; 543

Surveillance data in; 9

Chickens, Sentinel

See Sentinel Chicken Surveillance Programme

Child-care

Hepatitis A associated with, Queensland; 276

Hepatitis A associated with, Victoria; 116

Cholera

Epidemiology and prevention; 301

Gastroenteritis cases from Penang, Malaysia; 299

Overseas updates; 67, 93, 120, 149, 172, 198, 221, 263, 283, 305, 342, 355, 374, 390, 406, 483

Travel information; 300

Clostridium perfringens

Gastroenteritis outbreak and; 279

Clostridium tetani

See Tetanus

Corynebacterium diphtheriae

See Diphtheria

Crimean-Congo haemorrhagic fever

Overseas updates; 496

D

Dengue

Overseas updates; 305, 341, 374, 483, 495

Diphtheria

Diphtheria-like illness; 64

NHMRC recommendations on immunisation; 65

Overseas updates; 355

E

Ebola haemorrhagic fever

Overseas updates; 12, 119, 243, 482, 496, 524

Reston virus in monkeys; 221

Enterohaemorrhagic *Escherichia coli*

Japan outbreak; 355, 390

O157, Gold Coast outbreak; 236

Enterococci

Aminoglycoside resistance; 532

Vancomycin-resistant; 400, 402

Equine morbillivirus

Possible fruit bat reservoir host; 262, 476

Screening of bat carers; 477

Escherichia coli

O157, Gold Coast outbreak; 236

Ethnicity

Sexually transmissible disease surveillance and; 240

G

Gastroenteritis

Cases from Penang, Malaysia; 299

Outbreak, Victoria; 279

Rotavirus outbreak, Solomon Islands; 352

Salmonella Mbandaka outbreak and peanut butter; 326

Gonococcal surveillance reports; 412, 433, 499, 549

Gonococci

Antimicrobial resistance, Western Pacific Region, 1995; 425

H

Haemophilus influenzae type b

Vaccination coverage, Australian Capital Territory; 256

Haemorrhagic fevers in Africa; 260

Haemorrhagic fever with renal syndrome, Bosnia and Herzegovina; 93

Hantavirus

Overseas updates; 244

Hepatitis A

Associated with child-care centre, Queensland; 276

Associated with child-care centre, Victoria; 116

Hepatitis C

Risk factors; 384

Surveillance data in *CDI*; 11

Surveillance, enhanced, incident cases; 384, 388

Hib

See Haemophilus influenzae type b

HIV and AIDS

Ethnicity and sexually transmissible disease surveillance; 240

Global picture (editorial); 62

Global situation; 56, 59, 341

Surveillance data in *CDI*; 11

Surveillance reports; 46, 71, 125, 176, 225, 246, 268, 288, 358, 377, 409, 470, 486, 527, 547

Validation of reported HIV risk exposure, New South Wales; 2

WHO estimates of prevalence; 59

HIV

See HIV and AIDS

Human immunodeficiency virus

See HIV and AIDS

I

Immunisation

Accelerated primary schedule (letters); 199, 284

Adverse events following vaccination

See Adverse Events Following Vaccination Surveillance Scheme

Coverage, Illawarra and Shoalhaven; 217

Coverage, measuring; 219

Haemophilus influenzae type b coverage, Australian Capital Territory; 256

NHMRC recommendations on diphtheria; 65

NHMRC recommendations on tetanus; 220

Pertussis, acellular vaccines; 192

Register

See Australian Childhood Immunisation Register

Rotavirus vaccine development; 296

School entry certificates, New South Wales; 6

Tetanus, South Australia; 220

See also Influenza

Influenza

Impact and vaccines; 212

National Surveillance

Annual Report, 1995; 140

Surveillance data in *CDI*; 12

Surveillance reports; 247, 266, 289, 309, 330, 345, 359, 377, 394, 410, 432, 470

New Zealand updates; 327, 341

NHMRC recommendations on immunisation; 149, 215

Northern Hemisphere updates; 12, 42, 119, 146

Tropical surveillance; 282

Vaccine formula for northern winter, 1996-1997; 146

Vaccine formula for southern winter, 1996; 148, 214

Vaccine formula for Australian winter, 1997; 465

Instructions to authors, *CDI*; 13

J

Japanese B encephalitis virus

Overseas updates; 466

Torres Strait reappearance; 191

Vaccination against, Torres Strait; 188

K

Kangaroo meat and toxoplasmosis; 66

L

Laboratory Database of Organisms From Sterile Sites

Annual report 1994; 28

Peritoneal dialysate isolates, 1992-1994; 35

Surveillance data in *CDI*; 10

Surveillance reports; 18, 73, 127, 178, 227, 268, 311, 346, 379, 413

LabDOSS

See Laboratory Database of Organisms from Sterile Sites

LabWISE

See Virology and Serology Laboratory Reporting Scheme

Lassa fever

Overseas updates; 263, 283, 305, 355

Legionnaires' Disease

See Legionellosis

Legionellosis

Two linked cases, South Australia; 372

Listeriosis

Outbreak, South Australia; 465

Lyssavirus

Human case of encephalitis, Queensland; 504

Human health aspects of bat infection; 325, 535

Prevention of human infection; 505, 535

M

Malaria

Epidemiology in Australia, 1991-1995; 84

Correction; 121

Surveillance in Australia; 304

Surveillance, role of diagnostic reference laboratory; 302

World situation, 1993; 88

Meliodosis

In tropical Australia; 63

Meningitis

Viral, overseas updates; 374, 390, 406, 428

See also Meningococcal infection

Meningococcal infection

Africa; 171

Australia; 368

Correction; 390

Invasive disease, north Queensland, 1990-1994; 320

Overseas updates; 67, 120, 149, 172, 243, 263, 283, 341, 355, 390, 406

Western Sydney, outbreak; 389

Meningococcal isolate surveillance, Australia; 422

Methicillin-resistant *Staphylococcus aureus*

Emerging sodium fusidate resistance in Western Australia; 492

MRSA

See Methicillin-resistant Staphylococcus aureus

Mycobacterial Surveillance System, National

see National Mycobacterial Surveillance System

Mycobacterial tuberculosis

See Tuberculosis

N

National Health and Medical Research Council

Recommendations on diphtheria immunisation; 65

Recommendations on influenza immunisation; 149, 215

Recommendations on tetanus immunisation; 220

National Influenza Surveillance

See Influenza, National Surveillance

National Mycobacterial Surveillance System

Tuberculosis notifications in Australia, 1994; 108

National Neisseria Network

See Meningococcal isolate surveillance

National Notifiable Diseases Surveillance System

Annual report, 1995; 440

Surveillance data in *CDI*; 9

Surveillance reports; 19, 43, 68, 95, 122, 150, 172, 201, 222, 244, 264, 285, 306, 327, 342, 356, 374, 391, 407, 429, 466, 483, 496, 525, 544

Neisseria meningitidis

Strain differentiation; 369

See also Meningococcal infection

New South Wales

HIV, Validation of reported risk exposure; 2

Immunisation coverage, Illawarra and Shoalhaven; 217

Meningococcal infection, Western Sydney; 389

School entry immunisation certificates; 6

NHMRC

see National Health and Medical Research Council

Northern Territory

Influenza, tropical surveillance; 282

Melioidosis, in tropical Australia; 63

Scrub typhus, fatal case; 420

Notifiable Diseases

See National Notifiable Diseases Surveillance System

P

Peanut butter and *Salmonella* Mbandaka outbreak; 326

Peritoneal Dialysate Isolates, LabDOSS, 1992-1994; 35

Pertussis

Accelerated primary schedule (letters); 199, 284

Epidemiology and acellular vaccines; 192

Poliomyelitis

See also acute flaccid paralysis

Outbreak, Albania; 428

Progress towards eradication

Overseas updates; 93

Reporting cases of acute flaccid paralysis; 120

Polioviruses

Reporting isolates; 120

Q

Queensland

Aminoglycoside-resistant enterococci; 532

Campylobacteriosis, five year review; 478

Diphtheria-like illness; 64

Equine morbillivirus

Possible bat reservoir host; 262, 476

Screening of bat carers for; 477

Escherichia coli O157, Gold Coast outbreak; 236

Hepatitis A associated with child-care; 276

Japanese encephalitis reappearance, Torres Strait; 191

Japanese encephalitis vaccination, Torres Strait; 188

Lyssavirus, human case of encephalitis; 504

Meningococcal infection, north Queensland, 1990-1994; 320

Vancomycin-resistant enterococci; 400, 402

R

Readership survey, *CDI*; 39

Resistance, antibiotic

See Antibiotic resistance

Ross River virus

Outbreak, Western Australia; 119, 136

Rotavirus

Epidemiology and vaccine development; 296

Outbreak, Solomon Islands; 352

Rubella

Overseas updates; 172

S

Salmonella

Mbandaka outbreak and peanut butter; 326

School entry immunisation certificates; 6

Scrub typhus, fatal case in Northern Territory; 420

Sentinel Chicken Surveillance Programme

Surveillance data in *CDI*; 11

Surveillance reports; 71, 205, 291, 346, 360, 487, 549

Serious adverse events following vaccination

See Adverse Events Following Vaccination Surveillance Scheme

Sexually transmissible disease

Surveillance and ethnicity data; 240

Solomon Islands, rotavirus outbreak; 352

South Australia

Legionellosis, two linked cases; 372

Listeriosis outbreak; 465

Tetanus vaccination levels; 220

Staphylococcus aureus

Toxic shock syndrome in Australia and New Zealand 1990-1994; 336

Sterile Sites Surveillance

See Laboratory Database of Organisms from Sterile Sites

Streptococcus pyogenes

Toxic shock syndrome in Australia and New Zealand 1990-1994; 336

Surveillance

Data in *CDI*; 9

Malaria; 302, 304

Syphilis

See Treponema pallidum

T

Tetanus

NHMRC recommendations on immunisation; 220

Vaccination levels in South Australia; 220

Toxic shock syndrome

Australia and New Zealand 1990-1994; 336

Information service; 339

Testing; 340, 389

Toxoplasmosis

And kangaroo meat (letter); 66

Reply from author (letter); 66

Travel information

Cholera; 300

Tuberculosis

Notifications in Australia, 1994; 108

WHO global situation 1994; 164

Typhoid

Overseas updates; 67, 374

V

Vaccination

See Immunisation

Vancomycin-resistant enterococci; 400, 402

Venezuelan equine encephalitis

Overseas updates; 374

Victoria

Gastroenteritis outbreak; 279

Hepatitis A associated with child-care centre; 116

Vibrio cholerae O1

See Cholera

Vibrio cholerae O139

See Cholera

Virology and Serology Laboratory Reporting Scheme

Annual report, 1995; 507

Surveillance data in *CDI*; 10

Surveillance reports; 15, 47, 74, 99, 129, 153, 179, 205, 228, 248, 270, 291, 313, 331, 348, 361, 380, 395, 414, 434, 471, 488, 500, 528, 550

W

Western Australia

Ross River virus outbreak; 119, 136

MRSA, sodium fusidate resistance; 492

Whooping cough

See Pertussis

World Health Organization

Gonococci, antimicrobial resistance, Western Pacific Region, 1995; 425

HIV / AIDS global situation; 56

HIV, estimates of prevalence; 59

Malaria world situation, 1993; 88

Network on Antimicrobial Resistance Monitoring; 259

Tuberculosis global situation 1994; 164

Y

Yellow fever

Overseas updates; 12, 42, 93, 466, 496, 544

CDI AUTHOR INDEX, 1996

A

Adams David; 505
Allen Amanda; 400
Allworth Anthony; 504, 505
Andrews Graham; 440
Andrews Ross; 384, 440
Antony Jayne; 403
Arklay Antony; 477

B

Barnes Graeme; 296
Barnett Dianne; 188
Bates John; 236
Beaton Sheila; 35, 326
Bishop Ruth; 296, 352
Bodman Janet; 402, 532
Boyden Andrew; 326
Brenton Colleen; 299
Bugg Helen; 352
Burgess Margaret; 192

C

Cable John; 148
Cameron Scott; 326
Capon Anthony; 389
Carman Judy; 465
Crerar Scott; 9, 28, 325, 440
Curran Margaret; 9, 140, 384, 440, 507
Currie Bart; 63, 420

D

Dalton Craig; 505
Davison Rod; 66, 276
Davos Dianne; 465
Dedman Rodney; 326
Delroy Brian; 465
Densten Kylie; 279
Doyle Kevin; 505
Dunn Kevin; 505

E

Eckert Phil; 326
El-Saadi Ossama; 66, 276
Evans David; 9, 440
Ewald Dan; 188

F

Faoagali Joan; 402
Feldheim Jenny; 326
Ferreira Catherine; 279
Field Hume; 476
Forrest Jill; 192

G

Geary Alanna; 402
Gerrard John; 477
Gifford Sandra; 240
Griffith Julia; 279
Griggs Elizabeth; 2
Gust Ian; 505

H

Hall Robert; 219, 465
Halpin Kim; 476
Hampson Alan; 212
Hanna Jeffrey; 188, 191, 320
Hargreaves Jenny; 9
Harries Bronwen; 116, 326
Harrington Susan; 136
Harrison Michael; 64
Heath Tim; 389
Heaton Selena; 279, 326
Herceg Ana; 9, 39, 372, 403, 440, 544
Hewitt Moria; 389
Heymer Malcolm; 236
Hills Susan; 236
Hogg Geoff; 326
Holland Rosalind; 326, 465

J

Jalaludin Bin; 6, 389
Jane Dick; 505
Jasinska Eva; 136
Jelfs Jane; 389
Jennings Anthony; 400
Johansen Cheryl; 136
Johnston Fay; 282

K

Kaldor John; 62
Kassulke Desley; 276
Kelly Robyn; 236
Kempe Ann; 256
Kennet Margery; 403
Kerr Marianne; 389
Kirk Martyn; 326, 372
Krause Vicki; 420

L

Lanser Jan; 372, 465
Leckie Roziani; 6
Levy Michael; 2
Lightfoot Dianne; 326
Lim Irene; 465
Lindsay Michael; 119, 136
Lloyd Glenis; 217
Lo David; 420
Locarnini Stephen; 388
Longbottom Helen; 41, 84, 325, 403
Longhurst Debbie; 276
Lum Gary; 420

M

MacKenzie John; 505
Marks Paul; 420
Masendycz Paul; 352
McAnulty Jeremy; 388, 505
McCall Brad; 236, 320, 478
McDonald Ann; 2
McLennan Lyn; 326

Mead Cathy; 505

Menzies Robert; 2

Morgan John; 504

Moser Kim; 28

Munro Rosemary; 368, 389

Murphy Denise; 236, 320

Murphy Fiona; 465

Murray Chris; 326

Murray Keith; 504, 505

Myint Htoo; 440

N

Ng Sally; 326
Nguyen Oanh; 389

O

O'Brien Eddie; 256
Oliveira Nidia; 136
Oliver Graeme; 9, 108, 304, 326, 440

P

Paterson David; 299, 400, 532
Peel Margaret; 336
Phillips Debra; 191
Price Darren; 236

R

Raman Shanti; 2
Riley Thomas; 492
Roberts Leslee A; 35
Robinson Priscilla; 336
Robson Jennifer; 64, 66, 299, 340
Rodgers Elizabeth; 352
Rooney John; 325
Rose Nick; 326
Rouch Graham; 326, 336, 505

S

Scheil Wendy; 326
Selvey Linda; 477, 505
Shah Smita; 6
Shaw David; 465

Sheridan John; 505
 Sherlock Kevin; 400
 Shield Jack; 191
 Skowronski George; 336
 Sloan David; 199, 284
 Smith David; 136
 Sorakin Michael; 284
 Stafford Russell; 478
 Strain David; 236

T

Tallis Graham; 116
 Tan Agnes; 326
 Tapsall John; 368
 Taylor Roscoe; 64, 477
 Temple-Smith Meredith; 240
 Tenkate Thomas; 478
 Thong Mee Len; 532
 Thornber Peter; 325
 Torvaldsen Siranda; 492

Tribe Ingrid; 465

V

Veitch Mark; 116, 279
 Vulcanis Mary; 326

W

Walker Carolyn; 372
 Walker John; 302
 Watson Charles; 372
 Wells Rachel; 372
 Whelan Peter; 420
 Whitby Michael; 389, 400
 Wild Beryl; 166
 Wing Lindsay; 64
 Wright AE (Tony); 136

Y

Young Peter; 262, 476

CDI REVIEWERS, 1996

We gratefully acknowledge the assistance the following specialist reviewers have given in reviewing articles for *CDI* during 1996.

Jan Bell
 Sydney Bell
 Margaret Burgess
 John Carnie
 Peter Collignon
 Stephen Conaty
 Yvonne Cossart
 Craig Dalton
 Geoff Davis
 Ian Denham
 Mark Ferson

Gavin Frost
 Suzanne Garland
 Lyn Gilbert
 Gary Grohmann
 Dick Groot-Obbink
 Robert Hall
 Linda Halliday
 Jeffrey Hanna
 Geoff Hogg
 Bernie Hudson
 Bin Jalalundin

John Kaldor
 Ed Kraa
 Jeremy McAnulty
 Brad McCall
 Louise McDonnell
 Peter McIntyre
 John MacKenzie
 Angela Merianos
 Rosemary Munro
 Terry Nolan
 Mahomed Patel

Thomas Riley
 Christine Roberts
 Jenny Robson
 Greg Sam
 David Smith
 John Spicer
 Graham Tallis
 John Tapsall
 Susan Tiley
 Leigh Trevillian
 Jenny Williams

NOTICE TO READERS

A note from the Editor

Ana Herceg, Acting Editor, *CDI*

This is the last issue of *Communicable Diseases Intelligence (CDI)* for 1996. The editorial team of *CDI* would like to wish all our readers a very happy Christmas and best wishes for 1997. We would particularly like to thank all those readers who have contributed articles, editorials, correspondence, outbreak reports and surveillance reports to *CDI*.

The first issue of *CDI* for 1997 will be published on 9 January. You will notice that the publication day of *CDI* is changing from Monday to Thursday in 1997, in order to accommodate printing schedules. *CDI* will continue to be published every fortnight except for the fortnight of Christmas / New Year.

Finally, *CDI* will have a new cover and content design in 1997. As always, we would appreciate your comments on *CDI* in 1997.



OVERSEAS BRIEFS

Source: World Health Organization (WHO)

Yellow Fever, Ghana

A total of 27 cases of yellow fever with five deaths has been reported over a period of a few weeks in the Upper East Region of the country. Out of 15 blood samples tested, three were positive for yellow fever. Health authorities

have initiated a vaccination campaign of the population considered to be at risk. Some stocks of vaccine are already available and WHO is sending further supplies.

COMMUNICABLE DISEASES SURVEILLANCE

National Notifiable Diseases Surveillance System

The NNDSS is conducted under the auspices of the Communicable Diseases Network Australia New Zealand. The system coordinates the national surveillance of more than 40 communicable diseases or disease groups endorsed by the National Health and Medical Research Council (NHMRC). Notifications of these diseases are made to State and Territory health authorities under the provisions of their respective public health legislations. De-identified core unit data are supplied fortnightly for collation, analysis and dissemination. For further information, see CDI 1996;20:9-10.

Reporting period 10 to 23 November 1996

There were 2,522 notifications received for this two-week period (Tables 1, 2 and 3). The numbers of reports for

selected diseases have been compared with average data for this period in the previous three years (Figure 1).

Twenty-five notifications of measles were received in this period, 11 (44%) of which were for children under the age of 5 years. The number of cases remains low for the time of year (Figure 2).

Rubella was notified for 175 persons in this period. The number of notifications has risen in recent months but is below the level reported for the same period in the past two years (Figure 3). Eighty-four cases (48%) were for adults aged 15 to 24 years. There was a predominance of males, the male:female ratio being 2:1.

There were 324 cases of pertussis reported this period of which 60% were under the age of 20 years. Included were 137 notifications from Victoria where there is currently an outbreak.

Table 1. Notifications of diseases preventable by vaccines recommended by the NHMRC for routine childhood immunisation, received by State and Territory health authorities in the period 10 to 23 November 1996

DISEASE ¹	ACT	NSW	NT	Qld	SA	Tas	Vic	WA	TOTALS FOR AUSTRALIA ²			
									This period 1996	This period 1995	Year to date 1996	Year to date 1995
Diphtheria	0	0	0	0	0	0	0	0	0	0	1	0
<i>Haemophilus influenzae</i> b infection	0	0	0	0	0	0	0	0	0	2	48	61
Measles	0	4	5	6	0	2	6	2	25	41	459	1242
Mumps	0	2	1	NN	4	0	1	1	9	6	113	137
Pertussis	0	43	0	38	88	3	137	15	324	197	3373	3890
Rubella	1	10	0	76	51	3	22	12	175	389	2389	3696
Tetanus	0	0	0	0	0	0	0	0	0	1	2	4

NN Not Notifiable.

1. No notifications of poliomyelitis have been reported since 1986.

2. Totals comprise data from all States and Territories. Cumulative figures are subject to retrospective revision, so there may be discrepancies between the number of new notifications and the increment in the cumulative figure from the previous period.

Table 2. Notifications of other diseases received by State and Territory health authorities in the period 10 to 23 November 1996

DISEASE ¹	ACT	NSW	NT	Qld	SA	Tas	Vic	WA	TOTALS FOR AUSTRALIA ²			
									This period 1996	This period 1995	Year to date 1996	Year to date 1995
Arbovirus Infection (NEC) ^{3,4}	0	0	2	0	0	0	0	1	3	0	95	65
Barmah Forest virus infection	0	3	-	9	0	0	0	-	12	27	748	713
Ross River virus infection	0	10	3	28	0	1	0	6	48	59	7638	2523
Dengue	0	0	0	1	1	-	0	2	4	1	37	29
Campylobacteriosis ⁵	14	-	15	193	89	29	108	82	530	538	10657	9724
Chlamydial infection (NEC) ⁶	5	NN	16	184	0	13	56	39	313	341	6672	5714
Donovanosis	0	NN	0	0	NN	0	0	0	0	3	45	74
Gonococcal infection ⁷	0	19	33	41	0	1	4	31	129	145	3425	2854
Hepatitis A	2	19	4	22	5	0	8	2	62	66	2001	1388
Hepatitis B incident	0	0	0	1	0	0	0	1	2	14	179	290
Hepatitis C incident	0	1	0	-	0	0	-	-	1	2	29	65
Hepatitis C unspecified	9	NN	11	198	NN	26	38	23	305	399	8268	8722
Hepatitis (NEC)	0	0	0	0	0	0	0	NN	0	0	17	12
Legionellosis	0	2	0	2	3	0	2	1	10	6	165	147
Leptospirosis	0	1	0	1	0	2	4	0	8	7	210	122
Listeriosis	0	0	0	0	0	0	0	0	0	4	59	53
Malaria	1	5	3	13	0	0	6	2	30	36	780	586
Meningococcal infection	0	3	1	2	2	0	7	0	15	13	385	350
Ornithosis	0	NN	0	0	0	0	8	1	9	21	67	145
Q Fever	0	7	0	14	0	0	0	0	21	27	475	430
Salmonellosis (NEC)	2	40	11	94	20	6	18	16	207	222	5098	5403
Shigellosis ⁵	0	-	6	21	4	0	0	3	34	22	593	681
Syphilis	0	15	21	13	0	1	0	1	51	64	1328	1694
Tuberculosis	0	6	2	12	0	1	15	2	38	57	983	940
Typhoid ⁸	0	1	0	0	0	0	0	0	1	3	74	65
Yersiniosis (NEC) ⁵	0	-	0	7	4	0	0	0	11	8	247	283

1. For HIV and AIDS, see Tables 4 and 5. For rarely notified diseases, see Table 3.

2. Totals comprise data from all States and Territories. Cumulative figures are subject to retrospective revision so there may be discrepancies between the number of new notifications and the increment in the cumulative figure from the previous period.

3. Tas: includes Ross River virus and dengue.

4. NT, Vic and WA: includes Barmah Forest virus.

5. NSW: only as 'foodborne disease' or 'gastroenteritis in an institution'.

6. WA: genital only.

7. NT, Qld, SA and Vic: includes gonococcal neonatal ophthalmia.

8. NSW, Vic: includes paratyphoid.

NN Not Notifiable.

NEC Not Elsewhere Classified.


- Elsewhere Classified.

Table 3. Notifications of rare¹ diseases received by State and Territory health authorities in the period 10 to 23 November 1996

DISEASE ²	Total this period	Reporting States or Territories	Year to date 1996
Brucellosis	3	Qld	35
Chancroid	0		1
Cholera	0		4
Hydatid infection	1	Qld	35
Leprosy	0		9

1. Fewer than 60 cases of each of these diseases were notified each year during the period 1988 to 1995.
2. No notifications have been received during 1996 for the following rare diseases: botulism; lymphogranuloma venereum; plague; rabies; yellow fever; or other viral haemorrhagic fevers.

Figure 1. Selected National Notifiable Diseases Surveillance System reports, and historical data¹



1. The historical data are the averages of the number of notifications in 9 previous 2-week reporting periods: the corresponding periods of the last 3 years and the periods immediately preceding and following those.

Figure 2. Measles notifications, 1991 to 1996, by month of onset





Figure 3. Rubella notifications, 1994 to 1996, by month of onset



Forty-eight notifications of Ross River virus were received in this period. Included were several apparent clusters in the Statistical Divisions of Fitzroy, Queensland (8 cases); Brisbane, Queensland (7 cases); Wide Bay-Burnett, Queensland (4 cases); Far North Queensland (4 cases); and Northern New South Wales (3 cases). Numbers remain low which is usual for the time of year.

One hundred and twenty-nine cases of gonococcal infection were reported in this period. Sixty-four (50%) were for persons in the 15 to 24 years age group. The male: female ratio was 1.7:1. Twenty cases were reported from the Statistical Division of Far North Queensland, 33 from the Northern Territory, 14 from Sydney and 15 from Kimberley, Western Australia.

Legionellosis was notified for 10 persons in this period. All cases were in the 40 to 84 years age range. For the year to date a total of 165 notifications have been received, of which 81% were for persons over 50 years of age (Figure 4). Most reports (69%) were for males.

Fifteen cases of meningococcal disease were reported in this period, of which 9 (60%) were for children 2 years of age or under. The number of notifications has remained stable since August, after peaking in July (Figure 5).

HIV and AIDS Surveillance

National surveillance for HIV disease is coordinated by the National Centre in HIV Epidemiology and Clinical Research (NCHECR), in collaboration with State and Territory health authorities and the Commonwealth of Australia. Cases of HIV infection are notified to the National HIV Database on the first occasion of diagnosis in Australia, by either the diagnosing laboratory (ACT, New South Wales, Tasmania, Victoria) or by a combination of laboratory and doctor sources (Northern Territory, Queensland, South Australia, Western Australia). Cases of AIDS are notified through the State and Territory health authorities to the National AIDS Registry. Diagnoses of both HIV infection and AIDS are notified with the person's date of birth and name code, to minimise duplicate notifications while maintaining confidentiality.

Tabulations of diagnoses of HIV infection and AIDS are based on data available three months after the end of the reporting interval indicated, to allow for reporting delay and to incorporate newly available information. More detailed information on diagnoses of HIV infection and AIDS is published in the quarterly Australian HIV Surveillance Report, available from the National Centre in HIV Epidemiology and Clinical Research, 376 Victoria Street, Darlinghurst NSW 2010. Telephone: (02) 332 4648 Facsimile: (02) 332 1837.

HIV and AIDS diagnoses and deaths following AIDS reported for July 1996, as reported to 31 October 1996, are included in this issue of CDI (Tables 4 and 5).

Figure 4. Legionellosis notifications, 1996, by age group and sex




Figure 5. Meningococcal notifications, 1993 to 1996, by month of specimen collection




Table 4. New diagnoses of HIV infection, new diagnoses of AIDS and deaths following AIDS occurring in the period 1 July to 31 July 1996, by sex and State or Territory of diagnosis

		ACT	NSW	NT	Qld	SA	Tas	Vic	WA	TOTALS FOR AUSTRALIA			
										This period 1996	This period 1995	Year to date 1996	Year to date 1995
HIV diagnoses	Female	0	4	0	4	0	0	2	0	10	5	46	57
	Male	0	30	0	16	2	1	12	1	62	58	446	458
	Sex not reported	0	1	0	0	0	0	0	0	1	1	4	8
	Total ¹	0	36	0	20	2	1	14	1	74	64	497	525
AIDS diagnoses	Female	0	1	0	1	0	0	0	0	2	0	10	19
	Male	0	10	0	4	0	0	3	0	17	44	248	417
	Total ¹	0	11	0	5	0	0	3	0	19	44	258	437
AIDS deaths	Female	0	1	0	0	0	0	0	0	1	4	11	26
	Male	0	11	0	7	1	0	2	1	22	50	206	368
	Total ¹	0	12	0	7	1	0	2	1	23	54	217	395

1. Persons whose sex was reported as transsexual are included in the totals.

Table 5. Cumulative diagnoses of HIV infection, AIDS and deaths following AIDS since the introduction of HIV antibody testing to 31 July 1996, by sex and State or Territory

		ACT	NSW	NT	Qld	SA	Tas	Vic	WA	AUSTRALIA
HIV diagnoses	Female	15	569	3	102	44	4	169	73	979
	Male	171	10131	84	1634	577	75	3423	761	16856
	Sex not reported	0	2049	0	0	0	0	42	0	2091
	Total ¹	186	12757	87	1741	621	79	3643	836	19950
AIDS diagnoses	Female	5	138	0	30	18	2	48	17	258
	Male	76	3899	26	666	284	32	1372	293	6648
	Total ¹	81	4047	26	698	302	34	1427	312	6927
AIDS deaths	Female	2	102	0	24	13	2	37	11	191
	Male	50	2728	20	469	195	21	1083	217	4783
	Total ¹	52	2836	20	495	208	23	1126	229	4989

1. Persons whose sex was reported as transsexual are included in the totals.

Australian Sentinel Practice Research Network

The Australian Sentinel Practice Research Network (ASPREN) comprises 99 sentinel general practitioners from throughout the country. Approximately 9,000 consultations are recorded each week for 12 conditions. Of these, CDI reports the consultation rate for influenza, rubella, measles, chickenpox, pertussis and gastroenteritis. For further information including case definitions see CDI 1996;20:98-99.

Data for weeks 46 and 47 ending 17 November and 24 November 1996 respectively are included in this issue of CDI (Table 6). There has been no significant change in the rates of notifications of gastroenteritis over recent reporting periods. Consultation rates for chickenpox rose during week 47 compared with recent weeks, while

those for influenza-like illnesses have remained steady. The numbers of cases of pertussis and measles have remained low.

Table 6. Australian Sentinel Practice Research Network reports, weeks 46 and 47, 1996

Condition	Week 46, to 17 November 1996		Week 47, to 24 November 1996	
	Reports	Rate per 1,000 encounters	Reports	Rate per 1,000 encounters
Influenza	30	3.6	26	3.5
Rubella	4	0.5	6	0.8
Measles	0	0	1	0.1
Chickenpox	25	3.0	34	4.6
Pertussis	5	0.6	3	0.4
Gastroenteritis	148	17.9	126	17.2

Sentinel Chicken Surveillance Programme

AK Broom¹, JS Mackenzie², L Melville³, DW Smith⁴ and PI Whelan⁵

1. Department of Microbiology, The University of Western Australia
2. Department of Microbiology, The University of Queensland
3. Berrimah Agricultural Research Centre, Darwin, NT
4. PathCentre, Perth
5. Department of Health and Community Services, Darwin, NT.

Sentinel chicken flocks are used to monitor flavivirus activity in Australia. The main viruses of concern are Murray Valley encephalitis (MVE) and Kunjin which cause the potentially fatal disease Australian encephalitis in humans. Currently 23 flocks are maintained in the north of Western Australia, 8 in the Northern Territory and 10 in Victoria. The flocks in Western Australia and the Northern Territory are tested all year round but those in Victoria are tested only from November to March, during the main MVE risk season.

Results are coordinated by the Arbovirus Laboratory in Perth and reported bimonthly.

Sentinel chicken serology was carried out for 16 of the 22 flocks in Western Australia in September and October 1996. There were no seroconversions during this period. Twenty-one of the 22 flocks of sentinel chickens were replaced during September. Those at Port Hedland were not replaced. New flocks were established at Lombadine, an Aboriginal community in the West Kimberley, and at Nullagine in the Pilbara. There are now 23 flocks in the north of Western Australia.

Five flocks of sentinel chickens from the Northern Territory were also tested in September and October. During this period there were no seroconversions to flaviviruses.

Gonococcal surveillance

John Tapsall, The Prince of Wales Hospital, High Street, Randwick, NSW, 2031 for the Australian Gonococcal Surveillance Programme

The Australian Gonococcal Surveillance Programme (AGSP) reference laboratories in the various States and Territories report data on sensitivity to an agreed 'core' group of antimicrobial agents quarterly. The antibiotics which are currently routinely surveyed are the penicillins, ceftriaxone, ciprofloxacin and spectinomycin, all of which are administered as single dose regimens. When in vitro resistance to a recommended agent is demonstrated in 5% or more of isolates, it is usual to reconsider the inclusion of that agent in current treatment schedules. Additional data are also provided on other antibiotics from time to time. At present all laboratories also test isolates for the presence of high level resistance to the tetracyclines. Tetracyclines are however not a recommended therapy for gonorrhoea. Comparability of data is achieved by means of a standardised system of testing and a programme-specific quality assurance process. Because of the substantial geographic differences in susceptibility patterns in Australia, regional as well as aggregated data are presented.

Reporting period 1 April to 30 June 1996


The AGSP laboratories examined 710 isolates of *Neisseria gonorrhoeae* for sensitivity to the penicillins, ceftriaxone, quinolones and spectinomycin and for high level resistance to the tetracyclines in the June quarter of 1996.

Penicillins

The usefulness of this group of antibiotics (penicillin, ampicillin, amoxycillin) is progressively diminishing and is least effective in Sydney and Melbourne where about a quarter of all isolates are resistant by one or more mechanisms. Figure 6 shows the proportion of isolates fully sensitive, less sensitive or relatively resistant to the penicillins by chromosomal mechanisms and the proportion of penicillinase-producing gonococci (PPNG) in different regions and as aggregated data for Australia. PPNG and relatively resistant isolates usually fail to respond to therapy with the penicillins. Those in the fully sensitive and less sensitive categories (minimal inhibitory concentration - MIC ≤ 0.5 mg/L) usually respond to a regimen of standard treatment with the above penicillins.

There were 37 PPNG identified in this reporting period (5.2% of all isolates). These were found in all centres except Adelaide, with 14 PPNG reported from Sydney, 8 from Melbourne, 7 from Perth, 5 from the Northern Territory and lower numbers in the other centres. Infections with PPNG were acquired locally, and in Indonesia, the Philippines, Malaysia, Vietnam, China and Thailand. Fifty (7%) of all isolates were resistant to the penicillins by separate chromosomal mechanisms. These so-called CMRNG were present in all centres except Perth, but most prominent in Sydney (18 isolates, 13% of the total there) and Melbourne (23 isolates, 21%). Perhaps somewhat paradoxically, the

Figure 6. Penicillin resistance of gonococcal isolates for Australia and by region, 1 April to 30 June 1996



- FS Fully sensitive to penicillin, MIC ≤ 0.03 mg/L.
 LS Less sensitive to penicillin, MIC 0.06 - 0.5 mg/L.
 RR Relatively resistant to penicillin, MIC ≥ 1 mg/L.
 PPNG Penicillinase producing *Neisseria gonorrhoeae*.

proportion of isolates fully sensitive to penicillin increased in Sydney and Melbourne in this quarter.

Ceftriaxone and spectinomycin.

All isolates from all parts of Australia were sensitive to these injectable agents.

Quinolone antibiotics

Twenty-four isolates (3.4%) had altered resistance to this group of antibiotics (ciprofloxacin, norfloxacin and enoxacin), with half of these showing high level resistance (QRNG). High level resistance to the quinolones was present in strains from all centres. Nine QRNG (8.2%) were detected in Melbourne, 6 in Sydney (4.4%), 3 each in Darwin and Perth, 2 in Adelaide and one in Brisbane. Most infections with QRNG were acquired overseas, with China and the Philippines identified most often as countries of acquisition. Other sources of QRNG included Malaysia, Indonesia, Vietnam and Thailand.

High level tetracycline resistance

Thirty-four tetracycline-resistant *Neisseria gonorrhoea* (TRNG) were detected throughout Australia with isolates of this type again present in all centres. The highest proportion of TRNG was found in Sydney where the 11 TRNG represented 8.1% of all isolates. TRNG were also prominent in Perth (12 isolates, 6.6%) and there were 4 TRNG isolated in both Melbourne and Darwin. Overseas sources of TRNG most often identified were Vietnam and Indonesia. Local acquisition was also recorded.

Serious Adverse Events Following Vaccination Surveillance Scheme

The Serious Adverse Events Following Vaccination Surveillance Scheme is a national surveillance scheme which monitors the serious adverse events that occur rarely following vaccination. More details of the scheme were published in CDI 1995:19; 273-274.

Acceptance of a report does not imply a causal relationship between administration of the vaccine and the medical outcome, or that the report has been verified as to the accuracy of its contents.

It is estimated that 250,000 doses of vaccines are administered every month to Australian children under the age of six years.

Results for the reporting period 15 September to 23 November 1996

There were 14 reports of serious adverse events following vaccination for this reporting period. Reports were received from the Australian Capital Territory (1), the Northern Territory (3), South Australia (2), Tasmania (1), Victoria (3) and Western Australia (4).

The 14 reports included cases of persistent screaming, hypotonic/hyporesponsive episodes, convulsions and 4 'other' events (Table 7). The 'other' events included a severe local reaction and three episodes of acute urticarial rash, one with facial swelling.

Two children were hospitalised. All cases recovered.

LabWISE

The Virology and Serology Reporting Scheme, LabWISE, is a sentinel reporting scheme. Twenty-one laboratories contribute data on the laboratory identification of viruses and other organisms. Data are collated and published in Communicable Diseases Intelligence each fortnight. These data should be interpreted with caution as the number and type of reports received is subject to a number of biases. For further information, see CDI 1996;20:9-12.

There were 800 reports received in the CDI Virology and Serology Reporting Scheme in this period (Tables 8 and 9).


Laboratory reports of parvovirus for October are the highest recorded (Figure 7). The virus is presumed to be transmitted via respiratory secretions. Infection is most common in school aged children but can occur at any age. In the last fortnight, 26 reports were received, with diagnosis by IgM detection (25) and four-fold rise in titre (1).

There were 31 reports of influenza A for this reporting period. Diagnosis was by single high titre (28) and four-fold rise in titre (3).


There were 101 laboratory reports of *Bordetella pertussis* received in this fortnight, all but one were from Victoria. The increase in reports has been associated with an outbreak of pertussis in Victoria and may also reflect increased testing.

Table 7. Adverse events following vaccination for the period 15 September to 23 November 1996

Event	Vaccines					Reporting States or Territories	Total reports for this period
	DTP	DTP / Hib	DTP / OPV / Hib	DTP / OPV	MMR		
Persistent screaming	1		1	1		Tas, WA	3
Hypotonic/hyporesponsive episode	1	1	2		1	ACT, NT, SA, WA	5
Convulsions		2				Vic, WA	2
Other	1	1	1		1	NT, Vic	4
TOTAL	3	4	4	1	2		14

Figure 7. Parvovirus laboratory reports, 1993 to 1996, by month of specimen collection

In the last fortnight, 52 reports of *Mycoplasma pneumoniae* were received, with diagnosis by IgM detection (38), single high titre (13) and four-fold rise in titre (1). The highest attack rates are generally in persons aged 5 to 20 years, but *Mycoplasma pneumoniae* can occur at any age and may

Figure 8. *Mycoplasma pneumoniae* laboratory reports, 1992 to 1996, by month of specimen collection

cause particularly severe disease in neonates. Reports appear to have peaked in September and are now expected to decline (Figure 8).

Table 8. Virology and serology laboratory reports by State or Territory¹ for the reporting period 14 to 27 November 1996, historical data², and total reports for the year

	State or Territory ¹								Total this fortnight	Historical data ²	Total reported this year
	ACT	NSW	NT	Qld	SA	Tas	Vic	WA			
MEASLES, MUMPS, RUBELLA											
Measles virus				1					1	18.7	53
Mumps virus		1		1					2	2.3	37
Rubella virus		5		61	1	1	2		70	105.5	630
HEPATITIS VIRUSES											
Hepatitis A virus			2	7					9	17.7	376
ARBOVIRUSES											
Ross River virus			6	22			1		29	12.5	3,143
Barmah Forest virus				13					13	6.3	208
Flavivirus (unspecified)				1					1	1.2	23
ADENOVIRUSES											
Adenovirus type 2						1			1	2.2	31
Adenovirus type 3							1		1	1.5	69
Adenovirus type 8							2		2	.5	9
Adenovirus not typed / pending		1		13		1			15	55.5	1,287
HERPES VIRUSES											
Cytomegalovirus			2	15			3		20	60.7	1,438
Varicella-zoster virus		3	3	36		2	6		50	46.5	1,102
Epstein-Barr virus		14	2	89			8		113	79.0	1,959
OTHER DNA VIRUSES											
Parvovirus				23			3		26	5.8	218

Table 8. Virology and serology laboratory reports by State or Territory¹ for the reporting period 14 to 27 December 1996, historical data², and total reports for the year, continued

	State or Territory ¹								Total this fortnight	Historical data ²	Total reported this year
	ACT	NSW	NT	Qld	SA	Tas	Vic	WA			
PICORNA VIRUS FAMILY											
Coxsackievirus A16							1		1	.0	6
Coxsackievirus B2						1	1		2	1.0	14
Coxsackievirus B4							1		1	.2	6
Coxsackievirus B untyped / pending				2					2	.0	2
Poliovirus type 2 (uncharacterised)							1		1	1.7	16
Rhinovirus (all types)		5		2			3		10	36.8	659
Enterovirus not typed / pending				2					2	39.0	771
ORTHO / PARAMYXOVIRUSES											
Influenza A virus		2		29					31	8.7	1,501
Influenza B virus							2		2	3.8	56
Parainfluenza virus type 2							1		1	1.2	70
Parainfluenza virus type 3		2		8			6		16	45.5	657
Respiratory syncytial virus		2		7			1		10	46.0	4,087
OTHER RNA VIRUSES											
Rotavirus		1				6	1		8	74.0	1,545
Norwalk agent							6		6	2.3	38
OTHER											
Chlamydia trachomatis not typed		13	9	115		2	9		148	106.0	3,509
Chlamydia psittaci							6		6	11.5	83
Mycoplasma pneumoniae		6		14			32		52	18.3	773
Coxiella burnetii (Q fever)		5		4			2		11	10.3	179
Rickettsia australis		1							1	1.3	18
Rickettsia tsutsugamushi				2					2	.2	13
Bordetella pertussis				1			100		101	24.3	699
Bordetella species				25					25	13.7	275
Legionella longbeachae				1					1	.2	15
Legionella species				1					1	.5	11
Leptospira hardjo				1					1	.0	20
Leptospira species				2					2	1.3	59
Schistosoma species							3		3	4.7	233
TOTAL		61	24	498	1	14	202		800	868.3	25,898

1. State or Territory of postcode, if reported, otherwise State or Territory of reporting laboratory.

2. The historical data are the averages of the numbers of reports in 6 previous 2 week reporting periods: the corresponding periods of the last 2 years and the periods immediately preceding and following those.

Table 9. Virology and serology laboratory reports by contributing laboratories for the reporting period 14 to 27 November 1996

STATE OR TERRITORY	LABORATORY	REPORTS
New South Wales	Institute of Clinical Pathology & Medical Research, Westmead	16
	Royal Alexandra Hospital for Children, Camperdown	8
	Royal Prince Alfred Hospital, Camperdown	11
Queensland	Queensland Medical Laboratory, West End	482
	State Health Laboratory, Brisbane	67
Tasmania	Northern Tasmanian Pathology Service, Launceston	3
	Royal Hobart Hospital, Hobart	9
Victoria	Microbiological Diagnostic Unit, University of Melbourne	9
	Royal Children's Hospital, Melbourne	122
	Victorian Infectious Diseases Reference Laboratory, Fairfield Hospital	73
TOTAL		800